{
  "paper_metadata": {
    "pmid": "24101373",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": null,
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 21,
        "demographics": "Mean age 63.1 years, 13 males (61.9%), 8 females (38.1%)",
        "phenotype": "Non-Val30Met transthyretin amyloidosis"
      },
      "penetrance_data": {
        "total_carriers_observed": 21,
        "affected_count": 18,
        "unaffected_count": 3,
        "uncertain_count": null,
        "penetrance_percentage": 85.7,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Peripheral neuropathy, cardiac involvement",
          "evidence_sentence": "All patients except one reported symptoms of peripheral neuropathy, 13 of 21 (62 %) reported symptoms of cardiac involvement."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "Peripheral neuropathy, cardiac involvement",
          "evidence_sentence": "All patients except one reported symptoms of peripheral neuropathy, 13 of 21 (62 %) reported symptoms of cardiac involvement."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Peripheral neuropathy, cardiac involvement",
          "evidence_sentence": "All patients except one reported symptoms of peripheral neuropathy, 13 of 21 (62 %) reported symptoms of cardiac involvement."
        }
      ],
      "functional_data": {
        "summary": "Tafamidis effectively stabilized TTR associated with several non-Val30Met variants.",
        "assays": [
          "TTR stabilization assay",
          "Neuropathy Impairment Score (NIS)",
          "Norfolk Quality of Life\u2013Diabetic Neuropathy (Norfolk QOL-DN) questionnaire"
        ]
      },
      "segregation_data": "Not explicitly mentioned",
      "population_frequency": "Not provided",
      "evidence_level": "Moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "The study included patients with eight different non-Val30Met TTR mutations.",
      "key_quotes": [
        "The most common genetic variant associated with polyneuropathy is Val30Met (valine replaced by methionine at position 30 of the amino acid chain), which accounts for \u224885 % of TTR-FAP cases worldwide.",
        "TTR stabilization at Week 6 was achieved in 18 (94.7 %) of the 19 intent-to-treat patients for whom both baseline and Week 6 data were available."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Baseline demographic characteristics (intent-to-treat population)",
      "variants_extracted": 8
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 8,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data regarding TTR variants and penetrance were extracted."
  }
}